Nuclear Medicine Physician Salary Guide 2026: PET/CT, Theranostics, and PSMA Income

Nuclear medicine physician salary overview 2026

Nuclear medicine is a hybrid imaging and therapeutic specialty that is experiencing a significant renaissance driven by theranostics — the convergence of paired radiodiagnostic and radiotherapeutic agents targeting the same molecular receptor. Physicians who practice nuclear medicine come from two primary training pathways: radiology residency plus nuclear medicine or nuclear radiology fellowship, and nuclear medicine residency (a 4-year standalone residency). Mean total compensation in 2026 ranges from $290,000–$440,000 in academic settings and $320,000–$480,000 in employed community hospital, health system, and private group positions. Nuclear medicine is traditionally employed-model or academic, with limited private practice infrastructure — but the growth of radiopharmaceutical therapy (RPT) is beginning to create a distinct clinical service line that commands premium compensation and additional administrative/medical director roles.

Income by practice setting

• Academic nuclear medicine (medical school / NCI-designated cancer center): $290,000–$440,000; PET/CT and SPECT interpretation; RPT program (Lutathera, Xofigo, Lu-177 PSMA, I-131); radioiodine therapy for thyroid cancer; clinical research on novel radiopharmaceuticals; NIH and DOE grant funding for radiopharmaceutical development; lowest nominal income but strongest theranostics program access and research pipeline
• Employed community hospital nuclear medicine: $320,000–$460,000; primarily PET/CT interpretation and nuclear cardiology (MPI); thyroid uptake/scan and I-131 therapy; bone scan; FDG-PET for oncology staging and restaging; employed by hospital or radiology group with hospital contract; professional-component-only billing typical
• Private radiology group with nuclear medicine: $350,000–$500,000; group employed nuclear medicine physicians who interpret for hospitals and outpatient imaging centers; professional fee billing through the group; quality assurance program oversight; some groups adding RPT service lines with administrative stipend for nuclear medicine program medical director
• RPT / theranostics program medical director: $400,000–$550,000; administrative stipend $40,000–$100,000+ for medical director of institutional RPT program; program development, regulatory compliance (NRC license, state radioactive materials license), team leadership, and protocol management; as RPT volume grows (Lutathera, Lu-177 PSMA, future agents), the medical director role becomes increasingly compensated

Billing codes and revenue drivers

• FDG PET/CT — whole body oncology: CPT 78816; professional interpretation fee $250–$450; the most commonly performed nuclear medicine procedure nationally; oncology staging (lung, lymphoma, melanoma, colorectal, esophageal, head and neck), restaging, treatment response assessment; high volume at cancer centers and major health systems
• FDG PET/CT — limited area: CPT 78814 (skull base to mid-thigh) / 78815 (brain) / 78816 (whole body); $180–$400; region-limited studies for specific clinical indications
• PSMA PET/CT (Pylarify / LOCAMETZ): CPT 78816 (PET/CT, whole body) with PSMA radiotracer; professional fee $250–$450 interpretation; radiotracer cost (Pylarify $5,000–$8,000/dose) billed separately to insurer; Medicare and major commercial insurers now cover PSMA PET for initial staging (high-risk PCa), biochemical recurrence, and metastatic castration-resistant PCa (mCRPC); PSMA PET volume has grown explosively since FDA approval (May 2021 Gallium-68 PSMA-11, May 2021 Piflufolastat F-18 Pylarify); now one of the highest-volume nuclear medicine procedures at programs performing prostate oncology
• Amyloid PET (Amyvid/Vizamyl/NeuraCeq): CPT 78816; $250–$450 interpretation; FDA-approved for Alzheimer's amyloid plaque detection; Medicare coverage through Alzheimer's Focused Dementia Care planning program; demand growing with anti-amyloid therapy development (Leqembi, Kisunla)
• Tau PET (Tauvid): CPT 78816; interpretation $250–$450; Alzheimer's tau tangle imaging; niche indication currently; growing clinical evidence for staging AD pathology
• SPECT/CT — bone: CPT 78300 (bone scan, whole body) / 78315 (3-phase) / 78830 (SPECT/CT); $150–$350 professional fee; oncology bone metastasis surveillance, osteomyelitis, Paget's disease, pediatric bone pathology; declining volume as whole-body PET/CT replaces planar bone scans for many oncology indications
• Myocardial perfusion imaging (MPI): CPT 78451 (SPECT, single study) / 78452 (multiple studies) / 78453 / 78454; professional fee $300–$600; stress-rest perfusion study with Tc-99m sestamibi or tetrofosmin; nuclear cardiology is the highest-volume SPECT application nationally; stress agent injection (adenosine, regadenoson) and exercise testing billing additional
• Thyroid uptake and scan: CPT 78000 (uptake single) / 78001 (uptake multiple) / 78006 (scan + uptake); $150–$350; Graves' disease evaluation, thyroid nodule characterization, thyroiditis; high volume in endocrinology-referring institutions
• I-131 thyroid ablation (benign disease — Graves'/toxic nodule): CPT 79020; professional fee $400–$900; dosimetry and patient instruction included; radioiodine administration for hyperthyroidism
• I-131 thyroid ablation (differentiated thyroid cancer): CPT 79030 (diagnostic dose) / 79100 (therapeutic ablation); professional fee $600–$1,500; thyroid remnant ablation post-thyroidectomy; low-iodine diet + recombinant TSH or thyroid hormone withdrawal protocol management
• Lutathera (Lu-177 DOTATATE) PRRT: CPT 79999 (unlisted radiopharmaceutical therapeutic procedure) or emerging specific codes; drug cost $40,000–$60,000/cycle (4-cycle treatment); hospital or infusion center bills drug separately; physician professional fee $400–$800/cycle for PRRT administration and monitoring; NET (neuroendocrine tumor) patient management; highest-cost single radiopharmaceutical in standard clinical use
• Lu-177 PSMA therapy (Pluvicto): CPT 79999; drug cost $40,000–$60,000/cycle; mCRPC patients post-AR inhibitor and taxane; FDA approved March 2022; rapidly growing utilization driven by VISION trial data; nuclear medicine physicians manage dosimetry and administration; collaboration with medical oncology required; PSMA PET eligibility scan generates additional imaging billing before each therapy decision
• Radium-223 (Xofigo): CPT 79999; monthly IV injection; mCRPC with bone-predominant metastases; drug cost $8,000–$12,000/injection; 6-cycle course; physician administration oversight billing per cycle

Theranostics: the future of nuclear medicine income

Theranostics — the coupling of a diagnostic radiotracer and a therapeutic radiopharmaceutical targeting the same molecular receptor — is transforming nuclear medicine from a primarily diagnostic specialty into a major therapeutic discipline. The PSMA theranostic pair (Ga-68/F-18 PSMA PET for diagnosis → Lu-177 PSMA therapy for treatment) and the SSR theranostic pair (Ga-68 DOTATATE PET → Lu-177 DOTATATE PRRT) are now established clinical practice. A pipeline of next-generation theranostic agents is in Phase 2–3 trials: RYZ101 (Ac-225 DOTATATE), 177Lu-PSMA-I&T (Novartis PNT2002), FPI-2265 (Ac-225 PSMA), and others. Nuclear medicine physicians who establish expertise in RPT program management — patient selection, dosimetry, regulatory compliance, and treatment monitoring — are uniquely positioned for the highest-income and highest-complexity roles in the specialty's growing therapeutic arm. RPT programs at NCI cancer centers and major health systems are actively adding nuclear medicine physician capacity to meet demand.

Geographic variation in nuclear medicine compensation

• NCI-designated cancer centers and academic medical centers: $300,000–$480,000; highest RPT and PSMA PET volume; advanced theranostics programs; research radiopharmaceutical development; Lutathera and Lu-177 PSMA both require specialized infrastructure (lead-lined rooms, waste disposal, NRC licensing)
• Large community health system networks: $330,000–$480,000; PET/CT and nuclear cardiology volume driven by oncology and cardiology referral bases; some adding PSMA PET as community cancer center service; I-131 thyroid therapy widely available
• Rural and critical access: $320,000–$450,000; teleradiology/tele-nuclear medicine interpretation growing for rural hospitals without on-site nuclear medicine physicians; I-131 therapy limited to facilities with appropriate radiation safety infrastructure; mobile PET/CT units serve rural markets

What we see at Ava Health

Nuclear medicine is experiencing a demand surge that the traditional radiology group model has not fully adapted to. Theranostics programs require dedicated nuclear medicine physician oversight that goes beyond interpretation — treatment planning, dosimetry, patient education, and regulatory compliance are time-intensive functions that many radiology groups were not structured to support. Institutions building RPT programs are actively recruiting dedicated nuclear medicine physicians specifically for the therapeutic role, often at compensation above the standard nuclear medicine interpretation range. For nuclear medicine physicians positioning their careers, RPT fellowship or on-the-job RPT expertise (at an established Lutathera or Lu-177 PSMA program) is becoming the most valuable credential in the specialty — and the demand for that expertise is currently outpacing supply by a significant margin.

Related: Radiologist Salary Guide, Interventional Radiologist Salary Guide, Hematologist-Oncologist Salary Guide, Radiation Oncologist Salary Guide.